Cardiovascular Drugs and Therapy·27 AugCandidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence AppraisalReviewMechanismsPaper